The results revealed that the expression of NALCN was correlated with 6 immune subtypes in 14 cancer types, including BLCA, BRCA, CESC, COAD, HNSC, LGG, LIHC, LUAD, LUSC, mesothelioma (MESO), PCPG, prostate adenocarcinoma (PRAD), STAD, and UCEC (Figure 5A). This evidence concerns the gene NALCN and mesothelioma.